Assuming that MAP Pharmaceuticals’ Levadex inhaled dihydroergotamine for the treatment of migraine receives FDA approval, Allergan will market the product to pain specialists and neurologists in the US. MAP will handle marketing to primary care physicians in the United States and will retain all rights outside the US. MAP plans to submit an NDA for Levadex by the middle of 2011. Read the company’s press release.
Allergan to co-promote Levadex with MAP
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA